801 related articles for article (PubMed ID: 9875847)
21. A structural biologist's view of the oestrogen receptor.
Pike AC; Brzozowski AM; Hubbard RE
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):261-8. PubMed ID: 11162934
[TBL] [Abstract][Full Text] [Related]
22. Structural insights into Resveratrol's antagonist and partial agonist actions on estrogen receptor alpha.
Chakraborty S; Levenson AS; Biswas PK
BMC Struct Biol; 2013 Oct; 13():27. PubMed ID: 24160181
[TBL] [Abstract][Full Text] [Related]
23. Peptide antagonists of the human estrogen receptor.
Norris JD; Paige LA; Christensen DJ; Chang CY; Huacani MR; Fan D; Hamilton PT; Fowlkes DM; McDonnell DP
Science; 1999 Jul; 285(5428):744-6. PubMed ID: 10426998
[TBL] [Abstract][Full Text] [Related]
24. Temporally distinct and ligand-specific recruitment of nuclear receptor-interacting peptides and cofactors to subnuclear domains containing the estrogen receptor.
Schaufele F; Chang CY; Liu W; Baxter JD; Nordeen SK; Wan Y; Day RN; McDonnell DP
Mol Endocrinol; 2000 Dec; 14(12):2024-39. PubMed ID: 11117532
[TBL] [Abstract][Full Text] [Related]
25. Molecular basis of agonism and antagonism in the oestrogen receptor.
Brzozowski AM; Pike AC; Dauter Z; Hubbard RE; Bonn T; Engström O; Ohman L; Greene GL; Gustafsson JA; Carlquist M
Nature; 1997 Oct; 389(6652):753-8. PubMed ID: 9338790
[TBL] [Abstract][Full Text] [Related]
26. Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-alpha: regulation by phosphorylation sites in the A/B region depends on other receptor domains.
Dutertre M; Smith CL
Mol Endocrinol; 2003 Jul; 17(7):1296-314. PubMed ID: 12714702
[TBL] [Abstract][Full Text] [Related]
27. CIA, a novel estrogen receptor coactivator with a bifunctional nuclear receptor interacting determinant.
Sauvé F; McBroom LD; Gallant J; Moraitis AN; Labrie F; Giguère V
Mol Cell Biol; 2001 Jan; 21(1):343-53. PubMed ID: 11113208
[TBL] [Abstract][Full Text] [Related]
28. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC
Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635
[TBL] [Abstract][Full Text] [Related]
29. Dynamic stabilization of nuclear receptor ligand binding domains by hormone or corepressor binding.
Pissios P; Tzameli I; Kushner P; Moore DD
Mol Cell; 2000 Aug; 6(2):245-53. PubMed ID: 10983973
[TBL] [Abstract][Full Text] [Related]
30. Estrogen receptor dimerization: ligand binding regulates dimer affinity and dimer dissociation rate.
Tamrazi A; Carlson KE; Daniels JR; Hurth KM; Katzenellenbogen JA
Mol Endocrinol; 2002 Dec; 16(12):2706-19. PubMed ID: 12456792
[TBL] [Abstract][Full Text] [Related]
31. Multiplexed molecular interactions of nuclear receptors using fluorescent microspheres.
Iannone MA; Consler TG; Pearce KH; Stimmel JB; Parks DJ; Gray JG
Cytometry; 2001 Aug; 44(4):326-37. PubMed ID: 11500849
[TBL] [Abstract][Full Text] [Related]
32. Overexpression, purification, and crystal structure of native ER alpha LBD.
Eiler S; Gangloff M; Duclaud S; Moras D; Ruff M
Protein Expr Purif; 2001 Jul; 22(2):165-73. PubMed ID: 11437591
[TBL] [Abstract][Full Text] [Related]
33. Simulation of the different biological activities of diethylstilbestrol (DES) on estrogen receptor alpha and estrogen-related receptor gamma.
Nam K; Marshall P; Wolf RM; Cornell W
Biopolymers; 2003 Jan; 68(1):130-8. PubMed ID: 12579585
[TBL] [Abstract][Full Text] [Related]
34. Estrogen response element-dependent regulation of transcriptional activation of estrogen receptors alpha and beta by coactivators and corepressors.
Klinge CM; Jernigan SC; Mattingly KA; Risinger KE; Zhang J
J Mol Endocrinol; 2004 Oct; 33(2):387-410. PubMed ID: 15525597
[TBL] [Abstract][Full Text] [Related]
35. Crystal structure of a mutant hERalpha ligand-binding domain reveals key structural features for the mechanism of partial agonism.
Gangloff M; Ruff M; Eiler S; Duclaud S; Wurtz JM; Moras D
J Biol Chem; 2001 May; 276(18):15059-65. PubMed ID: 11278577
[TBL] [Abstract][Full Text] [Related]
36. Structural insights into selective agonist actions of tamoxifen on human estrogen receptor alpha.
Chakraborty S; Biswas PK
J Mol Model; 2014 Aug; 20(8):2338. PubMed ID: 25060147
[TBL] [Abstract][Full Text] [Related]
37. Identification of tamoxifen-induced coregulator interaction surfaces within the ligand-binding domain of estrogen receptors.
Heldring N; Nilsson M; Buehrer B; Treuter E; Gustafsson JA
Mol Cell Biol; 2004 Apr; 24(8):3445-59. PubMed ID: 15060164
[TBL] [Abstract][Full Text] [Related]
38. Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains.
Feil R; Wagner J; Metzger D; Chambon P
Biochem Biophys Res Commun; 1997 Aug; 237(3):752-7. PubMed ID: 9299439
[TBL] [Abstract][Full Text] [Related]
39. FLP recombinase/estrogen receptor fusion proteins require the receptor D domain for responsiveness to antagonists, but not agonists.
Nichols M; Rientjes JM; Logie C; Stewart AF
Mol Endocrinol; 1997 Jun; 11(7):950-61. PubMed ID: 9178754
[TBL] [Abstract][Full Text] [Related]
40. Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists.
Mahfoudi A; Roulet E; Dauvois S; Parker MG; Wahli W
Proc Natl Acad Sci U S A; 1995 May; 92(10):4206-10. PubMed ID: 7753783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
